Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

STRATEC sells Diatron and records large impairments

STRATEC has sold its subsidiary Diatron to an Indian investor consortium (fixed purchase price €10.0m plus performance‑related components); the OEM business for molecular and immunodiagnostics remains with STRATEC. Diatron is expected to generate around €20.0m in revenue in 2026 and an adjusted EBIT of about −€10.0m; STRATEC will record non‑cash impairments of €44.1m in Q3 2026 and expects a negative deconsolidation effect of €4.0–9.0m in Q4. After adjustments, STRATEC expects currency‑adjusted revenue for 2026 to be stable to slightly up and an adjusted EBIT margin of 13.0–15.0%; the previously communicated mid‑term targets are being withdrawn and will be updated with the 2026 annual report. » More on finanzen.net
Stratec gains 35% in three months and secures products under five-year contracts

Stratec, a developer and manufacturer of automation and diagnostic systems for in-vitro diagnostics, recorded a share-price gain of about 35% over the past three months. Management stresses that products are contractually secured for the next five years, meaning growth through 2030 is more firmly underpinned than current figures show. The focus is on the long-term outlook beyond 2026. » More on finanzen.net
STRATEC SE: Supervisory board member Ralf Leistner receives 29,556 shares as a gift

Ralf Leistner, member of the supervisory board of STRATEC SE, received a total of 29,556 shares of the company on 19 August 2026. The shares were transferred to him free of charge by Hermann Leistner and Doris Leistner as a gift. The transaction took place outside a trading venue and was published in accordance with reporting obligations. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, STRATEC has already paid €0.60 in dividends. The last payout was in June.

Financials

In the last quarter, STRATEC had revenue of €59.11m and net profit of €4.16m

(EUR)	June 2026	YoY
Revenue	59.11m	0.31%
Gross profit	15.24m	4.62%
Net profit	4.16m	219.91%
EBITDA	8.52m	14.11%

Fundamentals

Metric	Value
Market capitalization	€273.51m
Number of shares	12.16m
52-week high/low	€26.55 - €16.30
Dividend yield	2.47%
Dividends TTM	€0.60
Beta	0.85
P/E ratio	-562.50
PEG ratio	8.64
P/B ratio	1.15
P/S ratio	1.12

Company profile

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

Name	STRATEC
CEO	Marcus Wolfinger
Headquarters	Birkenfeld, rp Germany
Website	stratec.com
Sector	Health Care
Industry	Health Care Technology
IPO	16/06/2000
Employees	1,383